<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662019000300379</article-id>
<article-id pub-id-type="doi">10.24245/mim.v35i3.2443</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectos nefrológicos de los SGLT2. ¿Qué sabemos hasta ahora?]]></article-title>
<article-title xml:lang="en"><![CDATA[Nephrological effects of SGLT2. What do we know so far?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salinas-Lezama]]></surname>
<given-names><![CDATA[Erika]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Seniscal-Arredondo]]></surname>
<given-names><![CDATA[Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alarcón-Sotelo]]></surname>
<given-names><![CDATA[Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Greene]]></surname>
<given-names><![CDATA[Enrique Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Weber]]></surname>
<given-names><![CDATA[Federico Leopoldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>35</volume>
<numero>3</numero>
<fpage>379</fpage>
<lpage>388</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662019000300379&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662019000300379&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662019000300379&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La prevalencia de diabetes mellitus tipo 2 ha crecido de manera significativa, longitudinal y continua a lo largo de los años. Se infiere que el número de adultos con nefropatía diabética también aumentará. Por consiguiente, la nefropatía diabética conserva sustancial importancia en la salud global y existe gran necesidad de minimizar la morbilidad de este padecimiento. Los inhibidores del cotransportador de sodio-glucosa 2 (SGLT2) son la clase farmacológica incorporada más recientemente a los recursos terapéuticos de antidiabéticos orales. Su acción se basa en el bloqueo de los cotransportadores SGLT2 sodio-glucosa que se encuentran en la membrana luminal de las células del túbulo contorneado proximal. Reducen las tasas de hiper-glucemia en pacientes con diabetes mellitus tipo 2 al disminuir la reabsorción renal de glucosa, aumentando así la excreción urinaria de glucosa. Se han demostrado reducciones significativas en hemoglobina glucosilada (HbA1c), junto con disminución de glucosa sérica en ayuno y posprandial en pacientes con diabetes mellitus tipo 2. Aunque la eficacia de los inhibidores de SGLT2 se ve afectada por la función renal, se han realizado subanálisis que evidencian que los inhibidores SGLT2, incluso en el contexto de insuficiencia renal grado 3b o 4, tienen efectos neutros en HbA1c, pero mejoran los parámetros bioquímicos y disminuyen el peso. El objetivo de este artículo es revisar la bibliografía disponible en la actualidad de los efectos renales de los inhibidores de SGLT2.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Prevalence of type 2 diabetes has increased significantly. It is inferred that the number of adults with diabetic nephropathy will also increase. Therefore, diabetic nephropathy will gain importance in global health and there is a need to minimize morbidity associated to this disease. Sodium-glucose transporter type 2 (SGLT2) inhibitors are the latest pharmacologic class of oral antidiabetics. They act upon the inhibition of SGLT2 co-transporters located in the luminal membrane of cells in the proximal convoluted tubule. Significant reductions in glycated haemoglobin levels, along with lower fasting glucose levels have been associated to SGLT2 inhibitors. Efficacy of SGLT2 inhibitors is affected with kidney failure, nonetheless, a subgroup study showed that SGLT2 inhibitors administered in the context of kidney failure (KDIGO stage 3b or 4) have neutral effects over HbA1C levels, but positive effects over other biochemical parameters and weight loss. The objective of this article is to review literature of renal effects of SGLT2 inhibitors.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Diabetes mellitus]]></kwd>
<kwd lng="es"><![CDATA[nefropatía diabética]]></kwd>
<kwd lng="es"><![CDATA[antidiabéticos]]></kwd>
<kwd lng="es"><![CDATA[inhibidores de los cotransportadores sodio-glucosa 2]]></kwd>
<kwd lng="en"><![CDATA[Type 2 diabetes]]></kwd>
<kwd lng="en"><![CDATA[Diabetic nephropathy]]></kwd>
<kwd lng="en"><![CDATA[Antidiabetics]]></kwd>
<kwd lng="en"><![CDATA[Sodium-glucose transporter 2 inhibitors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>International Diabetes Federation</collab>
<source><![CDATA[IDF Diabetes Atlas]]></source>
<year>2015</year>
<edition>7</edition>
<publisher-name><![CDATA[International Diabetes Federation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Afkarian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zelnick]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[YN]]></given-names>
</name>
<name>
<surname><![CDATA[Heagerty]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tuttle]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2016</year>
<volume>316</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>602-10</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DeFronzo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[From the triumvirate to the ominous octet A new paradigm for the treatment of type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2009</year>
<volume>58</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>773-95</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Corkey]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Grant]]></surname>
<given-names><![CDATA[SFA]]></given-names>
</name>
<name>
<surname><![CDATA[Gavin]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The time is right for a new classification system for diabetes rationale and implications of the ß-cell-centric classification schema]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2016</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>179-86</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tuttle]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[DeFronzo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The natural history of diabetic nephropathy]]></article-title>
<source><![CDATA[Sem Nephrol]]></source>
<year>1990</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>184-93</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tuttle]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Billous]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Chiang]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[De Boer]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein-Fuchs]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetic kidney disease A report from an ADA consensus]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2014</year>
<volume>37</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>286-2883</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrianesis]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Glykofridi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Doupis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The renal effects of SGLT2 inhibitors and a mini review of the literature]]></article-title>
<source><![CDATA[Ther Adv Endocrinol Metab]]></source>
<year>2016</year>
<volume>7</volume>
<numero>5-6</numero>
<issue>5-6</issue>
<page-range>212-28</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dunsky]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrence]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal glycosuria]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>1947</year>
<volume>4</volume>
<page-range>416-21</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Bass]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Unwin]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-induced renal Fanconi syndrome]]></article-title>
<source><![CDATA[QJM: An Int J Med]]></source>
<year>2014</year>
<volume>107</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>261-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallo]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Vallon]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Probing SGLT2 as a therapeutic target for diabetes basic physiology and consequences]]></article-title>
<source><![CDATA[Diab Vasc Dis Res]]></source>
<year>2015</year>
<volume>12</volume>
<page-range>78-89</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Santer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rueff]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of kidney disease on glucose handling (including genetic defects)]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2011</year>
<page-range>S7-13</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quamme]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence for a high-affinity sodium-dependent D-glucose transport system in the kidney]]></article-title>
<source><![CDATA[Am J Physiol]]></source>
<year>1987</year>
<volume>253</volume>
<page-range>F151-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poudel]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition]]></article-title>
<source><![CDATA[Indian J Endocrinol Metabol]]></source>
<year>2013</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>588-93</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[10 Microvascular complications and foot care]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>S88-98</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Pharmacological approaches to glycemic control]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>S64-74</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rydén]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Grant]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Berne]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD the Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2013</year>
<volume>34</volume>
<numero>39</numero>
<issue>39</issue>
<page-range>3035-87</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zinman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wanner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lachin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Fitchett]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bluhmki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hantel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2015</year>
<volume>373</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2117-28</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[De Zeeuw]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fulcher]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CANVAS Program Collaborative Group Canagliflozin and cardio vascular and renal events in type 2 diabetes]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>644-57</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mosley]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Everton]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fellner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes a drug class overview]]></article-title>
<source><![CDATA[PT]]></source>
<year>2015</year>
<volume>40</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>451-62</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lioudaki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Whyte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Androulakis]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Stylianou]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Daphnis]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Ganotakis]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal effects of SGLT-2 inhibitors and other anti-diabetic drugs: clinical relevance and potential risks]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2017</year>
<numero>3</numero>
<issue>3</issue>
<page-range>470-80</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sasson]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Cherney]]></surname>
<given-names><![CDATA[DZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal hyperfiltration related to diabetes mellitus and obesity in human disease]]></article-title>
<source><![CDATA[World J Diabetes]]></source>
<year>2012</year>
<volume>3</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kojima]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Slaughter]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats]]></article-title>
<source><![CDATA[Physiological Reports]]></source>
<year>2015</year>
<volume>3</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Terami]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abassi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Os 05-04 empagliflozin exerts cardio- and nephroprotective effects in Cohen-Rosenthal diabetic hypertensive rats]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2016</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e58-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Panchapakesan]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wanner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Lachin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Fitchett]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Von Eynatten]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Mattheus]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EMPA-REG OUTCOME Investigators Empagliflozin and progression of kidney disease in type 2 diabetes]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>323-34</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogawa]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sakaguchi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors possible mechanism and contributing factors]]></article-title>
<source><![CDATA[J Diabetes Investig]]></source>
<year>2016</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>135-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chou]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Seak]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ning]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Euglycemic diabetic ketoacidosis caused by dapagliflozin]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2018</year>
<volume>97</volume>
<numero>25</numero>
<issue>25</issue>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benmoussa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Penmetsa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Euglycemic diabetic ketoacidosis The clinical concern of SGLT2 inhibitors]]></article-title>
<source><![CDATA[J Clin Transl Endocrinol: Case Reports]]></source>
<year>2016</year>
<volume>2</volume>
<page-range>17-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Banks]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Buse]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fulcher]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of sotagliflozin added to insulin in patients with type 1 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<page-range>2337-48</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Bommel]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Muskiet]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Tonneijck]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Nieuwdorp]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Van Raalte]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibition in the dia- betic kidney-from mechanisms to clinical outcome]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2017</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>700-10</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vasilakou]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Karagiannis]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Athanasiadou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mainou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Liakos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bekiari]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2013</year>
<volume>159</volume>
<page-range>262-74</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vivian]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium-glucose co-transporter 2 (SGLT2) inhibitors A growing class of antidiabetic agents]]></article-title>
<source><![CDATA[Drugs Context]]></source>
<year>2014</year>
<volume>3</volume>
<page-range>212-64</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheen]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of reducing blood pressure on cardio-vascular outcomes and mortality in patients with type 2 diabetes Focus on SGLT2 inhibitors and EMPA-REG OUTCOME]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2016</year>
<volume>121</volume>
<page-range>204-14</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Afkarian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sachs]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Kestenbaum]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsch]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Tuttle]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Himmelfarb]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de Boer]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[H Kidney disease and increased mortality risk in type 2 diabetes]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2013</year>
<volume>24</volume>
<page-range>302-8</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muskiet]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Tonneijck]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Smits]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Van Raalte]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pleiotropic effects of type 2 diabetes management strategies on renal risk factors]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2015</year>
<volume>3</volume>
<page-range>367-81</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
